2025年2月19日 · The Infectious Diseases Society of America (IDSA) is no longer accepting comments on the 2025 updated Guideline on the Management and Treatment of Complicated Urinary Tract Infections (cUTI). This update provides clinical practice guidelines for patients with cUTI, with and without sepsis.

The U.S. Food and Drug Administration has approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI)...

2025年2月20日 · The Infectious Diseases Society of America (IDSA) has announced that the 2025 Guideline on the Management and Treatment of Complicated Urinary Tract Infections (cUTI) is now open for public comment. This update provides clinical practice guidelines for patients with cUTI, with and without sepsis.

We consider the treatment of cUTIs to be an indication distinct from the treatment of uncomplicated urinary tract infections. This guidance addresses cUTI only.

ZERBAXA is indicated for the treatment of adult and pediatric patients (birth to less than 18 years old) with complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa.

Current evidence underscores the need for antimicrobial stewardship, precise diagnostics, and innovative therapies to address cUTI while mitigating antimicrobial resistance. A targeted, patient-centered approach is essential to optimize outcomes and reduce the burden of …

Finafloxacin has proven activity against slowly growing bacteria and biofilms often found in catherterized cUTI patients. Finafloxacin has the potential to be ‘carbapenem sparing’ and saving other novel antibiotics targeting multidrug resistant pathogens.

We provide evidence in favor of the adoption of MV as a first-choice treatment of carbapenem-resistant cUTI, and ETPM, BAPM, and MEPM as another reasonable choice for cUTI empiric therapy. This therapeutic option is supported by available clinical data from different sources.

2025年3月3日 · Data are limited regarding use of narrow-spectrum agents for the treatment of complicated urinary tract infections (cUTIs). We sought to evaluate cefazolin compared with ceftriaxone for the empiric treatment of patients with cUTIs in an inpatient setting. We conducted a retrospective, single-center, cohort study involving patients with cUTI treated with cefazolin or ceftriaxone at a Veterans ...

2025年1月16日 · Complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP, kidney infections) have a high risk of treatment failure, requiring longer courses of antibiotic treatment.